Glenn J. Hanna, MD, Dana-Farber Cancer Institute

Articles

Dr. Hanna on the Efficacy of Tipifarnib in HRAS-Mutated Head and Neck Cancer

November 10th 2021

Glenn J. Hanna, MD, discusses promising data reported with tipifarnib in patients with HRAS-mutated head and neck cancer.

Dr. Hanna on the Role of Second-Line Cetuximab in Head and Neck Cancer

November 4th 2021

Glenn J. Hanna, MD, discusses the role of second-line cetuximab (Erbitux) in head and neck cancer.

Managing Adverse Events With Tipifarnib

July 19th 2021

Recommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.

Future Directions in HRAS-Mutated Head and Neck Cancer

July 19th 2021

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, highlight potential new therapies for head and neck squamous cell carcinoma in various patient populations.

Pivotal AIM-HN Clinical Trial of Tipifarnib in HNSCC

July 19th 2021

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, discuss the design and potential clinical implications of the AIM-HN trial of tipifarnib in head and neck cancers.

Tipifarnib in HRAS-Mutated HNSCC

July 19th 2021

Potential implications for treating patients with HRAS-mutated head and neck cancer with tipifarnib, based on results demonstrated by the RUN-HN study.

Molecular Testing in HNSCC

July 19th 2021

Guidance for incorporating initial and repeat molecular testing in head and neck cancers into clinical practice.

The Evolving Treatment Landscape of HNSCC

July 19th 2021

A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma.